PharVision Advisers’s Synovus SNV Stock Holding History

PharVision Advisers’s Portfolio SNV Stock Details SNV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,352	Closed	-$225K	–	785
2025 Q2	$225K	Buy	+4,352	New	+$200K	0.32%	167

Other funds holding SNV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Synovus Financial Columbus, Georgia $8.74B AUM 12.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's SNV Position: Q3 2025 in Review

PharVision Advisers sold out of Synovus (SNV) in Q3 2025, closing a stake of 4,352 shares — an estimated $225K sold.

PharVision Advisers first reported a position in SNV in Q2 2025 and held it in 1 quarter. The position peaked at $225K in Q2 2025. 486 funds tracked by Wall St. Rank hold SNV as of Q3 2025.

PharVision Advisers reported no remaining Synovus position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 4,352 Synovus shares in Q3 2025, an estimated $225K.
PharVision Advisers first reported a position in Synovus in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Synovus position peaked at $225K in Q2 2025.
486 funds tracked by Wall St. Rank held Synovus as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.